Dare Bioscience Inc (DARE)

$1.98 -0.09 (-4.35%)
Market Cap 29.58M
Revenue (ttm) 10,000.00
Net Income (ttm) -4.05M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 1.60
Profit Margin -40,500.00%
Debt to Equity Ratio 0.00
Volume 27,100
Avg Vol 181,554
Day's Range N/A - N/A
Shares Out 14.29M
Stochastic %K 36%
Beta 0.78
Analysts Strong Sell
Price Target $10.75

Company Profile

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual aro...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 926 7655
Address:
3655 Nobel Drive, Suite 260, San Diego, United States
BiotechJedi1728
BiotechJedi1728 Jan. 9 at 12:01 AM
$DARE In case people are wondering. https://www.linkedin.com/posts/dare-bioscience_opportunity-to-invest-in-dar%C3%A9-bioscience-activity-7415141766380806144--uYv?utm_source=share&utm_medium=member_ios&rcm=ACoAAACdVpABt6kGksglM6yOtoqYXdcE9HE9y_M
1 · Reply
JohnTrack
JohnTrack Jan. 6 at 4:55 PM
$DARE updated corporate presentation https://www.rapidticker.com/news/dare-sec-filing-c7a448
0 · Reply
Tdemo12
Tdemo12 Jan. 6 at 3:46 PM
@walfofwallstreet anything you know about $DARE ?
0 · Reply
zhusjason1
zhusjason1 Jan. 5 at 8:00 PM
$DARE Charting, candling don’t work for bioscience companies, numbers and products are all we care.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 5 at 5:54 PM
$DARE RSI: 24.49, MACD: 0.0134 Vol: 0.19, MA20: 2.09, MA50: 1.95 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 1 at 2:52 AM
$DARE
0 · Reply
RMAW
RMAW Dec. 31 at 8:56 PM
$DARE 2026 is our breakout year!!! 🤪
0 · Reply
IceBison
IceBison Dec. 31 at 3:04 PM
$DARE when FDA approval and revenue follow, this girl will fly to the moon, 10x in couple years
0 · Reply
IceBison
IceBison Dec. 31 at 12:43 AM
$DARE started a position 1k shares @ $1.98. let see how it goes. I think company should research a kind of perfume that makes women want to have sex when they smell it. That perfume will be hot sale on earth. I will buy it in a heartbeat
0 · Reply
StrangleShares
StrangleShares Dec. 26 at 3:43 PM
$DARE Risk appetite is present but conditioned on validation. Margin trajectory needs to confirm that scale creates leverage, not dilution. Missteps would reset expectations abruptly. Without validation, volatility will remain persistent.
0 · Reply
Latest News on DARE
DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility

Dec 10, 2025, 8:00 AM EST - 4 weeks ago

DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility

Daré Bioscience, Inc. (DARE) Discusses DARE to PLAY Sildenafil Cream as a Treatment Option for Female Genital Arousal Concerns Transcript

Nov 22, 2025, 7:23 AM EST - 6 weeks ago

Daré Bioscience, Inc. (DARE) Discusses DARE to PLAY Sildenafil Cream as a Treatment Option for Female Genital Arousal Concerns Transcript

Daré Bioscience, Inc. (DARE) Q3 2025 Earnings Call Transcript

Nov 13, 2025, 7:41 PM EST - 2 months ago

Daré Bioscience, Inc. (DARE) Q3 2025 Earnings Call Transcript

Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 13, 2025, 4:01 PM EST - 2 months ago

Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025

Nov 6, 2025, 8:00 AM EST - 2 months ago

Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025

Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research

Sep 24, 2025, 8:00 AM EDT - 3 months ago

Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research

Daré Bioscience, Inc. (DARE) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 7:48 PM EDT - 5 months ago

Daré Bioscience, Inc. (DARE) Q2 2025 Earnings Call Transcript

Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 14, 2025, 4:01 PM EDT - 5 months ago

Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025

Aug 7, 2025, 8:00 AM EDT - 5 months ago

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025

Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

Jul 29, 2025, 8:00 AM EDT - 5 months ago

Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

Jul 21, 2025, 1:47 PM EDT - 6 months ago

UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

Crude Oil Moves Lower; Daré Bioscience Shares Jump

Jul 14, 2025, 1:09 PM EDT - 6 months ago

Crude Oil Moves Lower; Daré Bioscience Shares Jump

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

Jul 14, 2025, 8:00 AM EDT - 6 months ago

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

Jul 11, 2025, 8:00 AM EDT - 6 months ago

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

Jun 12, 2025, 5:00 PM EDT - 7 months ago

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

Daré Bioscience, Inc. (DARE) Q1 2025 Earnings Call Transcript

May 13, 2025, 11:13 PM EDT - 8 months ago

Daré Bioscience, Inc. (DARE) Q1 2025 Earnings Call Transcript

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

May 13, 2025, 4:01 PM EDT - 8 months ago

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

Daré Bioscience, Inc. (DARE) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 10:14 PM EDT - 10 months ago

Daré Bioscience, Inc. (DARE) Q4 2024 Earnings Call Transcript

Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

Mar 31, 2025, 4:01 PM EDT - 10 months ago

Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025

Mar 24, 2025, 8:00 AM EDT - 10 months ago

Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development

Feb 6, 2025, 8:00 AM EST - 1 year ago

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development

Daré Bioscience to Participate in the Women's Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 9, 2025, 8:00 AM EST - 1 year ago

Daré Bioscience to Participate in the Women's Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

Daré Bioscience, Inc. (DARE) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 8:03 PM EST - 1 year ago

Daré Bioscience, Inc. (DARE) Q3 2024 Earnings Call Transcript

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update

Nov 14, 2024, 4:01 PM EST - 1 year ago

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update

Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024

Nov 7, 2024, 8:00 AM EST - 1 year ago

Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024

Daré Bioscience Selected to Receive $10 Million Award from ARPA-H's Sprint for Women's Health

Oct 23, 2024, 12:30 PM EDT - 1 year ago

Daré Bioscience Selected to Receive $10 Million Award from ARPA-H's Sprint for Women's Health

Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

Oct 21, 2024, 8:05 AM EDT - 1 year ago

Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

Daré Bioscience, Inc. (DARE) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 8:40 PM EDT - 1 year ago

Daré Bioscience, Inc. (DARE) Q2 2024 Earnings Call Transcript

Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update

Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule

Jul 19, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors

Jul 1, 2024, 6:54 AM EDT - 1 year ago

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors

KPRX

Daré Bioscience Announces Reverse Stock Split

Jun 27, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Announces Reverse Stock Split

Daré Bioscience, Inc. (DARE) Q1 2024 Earnings Call Transcript

May 14, 2024, 6:30 PM EDT - 1 year ago

Daré Bioscience, Inc. (DARE) Q1 2024 Earnings Call Transcript

Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

May 14, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network

May 2, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates through Key Catalysts

Apr 30, 2024, 7:30 AM EDT - 1 year ago

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates through Key Catalysts

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Apr 23, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Apr 11, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Daré Bioscience, Inc. (DARE) Q4 2023 Earnings Call Transcript

Mar 28, 2024, 8:47 PM EDT - 1 year ago

Daré Bioscience, Inc. (DARE) Q4 2023 Earnings Call Transcript

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Mar 28, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024

Mar 21, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024

This overlooked corner of women's health could be a $350 billion market opportunity

Mar 15, 2024, 2:33 PM EDT - 1 year ago

This overlooked corner of women's health could be a $350 billion market opportunity

PFE PGNY VTGN BTMD

Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

Jan 31, 2024, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

Daré Bioscience Announces Executive Team and Board of Directors Changes

Jan 26, 2024, 4:30 PM EST - 2 years ago

Daré Bioscience Announces Executive Team and Board of Directors Changes

Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

Jan 17, 2024, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

Daré Bioscience's DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women's Health as well as in Treating a Broad Range of Diseases

Jan 4, 2024, 8:00 AM EST - 2 years ago

Daré Bioscience's DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women's Health as well as in Treating a Broad Range of Diseases

Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

Dec 26, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study

Dec 20, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study

Dec 13, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study

Daré Bioscience, Inc. (DARE) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 9:56 PM EST - 2 years ago

Daré Bioscience, Inc. (DARE) Q3 2023 Earnings Call Transcript

BiotechJedi1728
BiotechJedi1728 Jan. 9 at 12:01 AM
$DARE In case people are wondering. https://www.linkedin.com/posts/dare-bioscience_opportunity-to-invest-in-dar%C3%A9-bioscience-activity-7415141766380806144--uYv?utm_source=share&utm_medium=member_ios&rcm=ACoAAACdVpABt6kGksglM6yOtoqYXdcE9HE9y_M
1 · Reply
JohnTrack
JohnTrack Jan. 6 at 4:55 PM
$DARE updated corporate presentation https://www.rapidticker.com/news/dare-sec-filing-c7a448
0 · Reply
Tdemo12
Tdemo12 Jan. 6 at 3:46 PM
@walfofwallstreet anything you know about $DARE ?
0 · Reply
zhusjason1
zhusjason1 Jan. 5 at 8:00 PM
$DARE Charting, candling don’t work for bioscience companies, numbers and products are all we care.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Jan. 5 at 5:54 PM
$DARE RSI: 24.49, MACD: 0.0134 Vol: 0.19, MA20: 2.09, MA50: 1.95 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
SuperGreenToday
SuperGreenToday Jan. 1 at 2:52 AM
$DARE
0 · Reply
RMAW
RMAW Dec. 31 at 8:56 PM
$DARE 2026 is our breakout year!!! 🤪
0 · Reply
IceBison
IceBison Dec. 31 at 3:04 PM
$DARE when FDA approval and revenue follow, this girl will fly to the moon, 10x in couple years
0 · Reply
IceBison
IceBison Dec. 31 at 12:43 AM
$DARE started a position 1k shares @ $1.98. let see how it goes. I think company should research a kind of perfume that makes women want to have sex when they smell it. That perfume will be hot sale on earth. I will buy it in a heartbeat
0 · Reply
StrangleShares
StrangleShares Dec. 26 at 3:43 PM
$DARE Risk appetite is present but conditioned on validation. Margin trajectory needs to confirm that scale creates leverage, not dilution. Missteps would reset expectations abruptly. Without validation, volatility will remain persistent.
0 · Reply
BiotechJedi1728
BiotechJedi1728 Dec. 25 at 6:41 PM
$DARE Merry Christmas shareholders and real investors.🎄May our new year be blessed with healthy, happy, and sexy women. May shorters and losers have dry, cold women and no sex at all. Life is beautiful, don’t let the losers get you down.
1 · Reply
Stormy02
Stormy02 Dec. 24 at 3:43 PM
Happy Holidays!! BIG BOYS' signature selections:​ $MWYN - The Board approved Subsidiary Formation for E-Waste Business. Possible partnership. $KULR - The shorts to go away. $AREC - Closed the $33M PIPE financing to support rare earth extraction and processing efforts. Strong Buy with a 12-month price target around ~$5–$6 . $DARE - Bill & Melinda Gates Foundation Funding Up to ~$10.7 million grant, of about $3.6 million paid in late 2025. $BYND - The stock is oversold.
1 · Reply
Stormy02
Stormy02 Dec. 22 at 5:25 PM
BIG BOYS' signature selections:​ $MWYN - The Board approved Subsidiary Formation for E-Waste Business. Possible partnership announcements for E-Waste. $KULR - The shorts to go away. $AREC - Closed the $33M PIPE financing to support rare earth extraction and processing efforts. Strong Buy with a 12-month price target around ~$5–$6 . $DARE - Bill & Melinda Gates Foundation Funding Up to ~$10.7 million grant, of about $3.6 million paid in late 2025. $BYND - The stock is oversold.
0 · Reply
zhusjason1
zhusjason1 Dec. 19 at 6:57 PM
$DARE I’m super happy with $25 and get out completely and never return.
0 · Reply
BiotechJedi1728
BiotechJedi1728 Dec. 19 at 1:05 PM
$DARE Big week indeed https://www.linkedin.com/posts/dare-bioscience_weve-had-a-big-week-we-announced-last-week-activity-7407441832235675648-HeYQ?utm_medium=ios_app&rcm=ACoAAACdVpABt6kGksglM6yOtoqYXdcE9HE9y_M&utm_source=social_share_send&utm_campaign=share_via
0 · Reply
1403tage
1403tage Dec. 17 at 5:15 PM
0 · Reply
ShiningInvestor
ShiningInvestor Dec. 17 at 3:53 PM
$DARE already up 10% 🎉
0 · Reply
alexrs
alexrs Dec. 17 at 3:31 PM
$DARE This aged well.
0 · Reply
ShiningInvestor
ShiningInvestor Dec. 17 at 2:46 PM
$DARE Short squeeze is loading fast! Today will be fun!
0 · Reply
ShiningInvestor
ShiningInvestor Dec. 17 at 2:41 PM
$DARE I wouldn’t dare to play short with this gem right now ☺️
0 · Reply
ShiningInvestor
ShiningInvestor Dec. 17 at 1:58 AM
$DARE The next leg up to $3+ should be between Wednesday and end of this week. Dare to Play is very underestimated with this market cap. Today was the day of consolidation.
0 · Reply
Green_Party
Green_Party Dec. 16 at 10:03 PM
$DARE Curious to see where this goes the next few months. My guesses: - Possible pops when they announce Dare to Play for all 50 states. - Possible catalyst when they announce plans for Phase 3 study. They kind of have to do Phase 3's, Sabrina advertised the whole thing as "backed by data" and I'm sure they want insurance coverage. So they gotta find some way to fund it, which could be big. Maybe some catalysts in mid/late January leading to an earnings run up in February? 🤞
1 · Reply